By The McReport Staff Researchers investigating the long-term impacts of COVID-19 have identified a promising new lead in the fight against long COVID. A study conducted using specialized mouse models (known as db/db mice, which mimic human type 2 diabetes) found that GLP-1 receptor agonists: the class of drugs that includes medications like Ozempic and Wegovy: significantly reduced the severity of lung scarring after infection with SARS-CoV-2. Pulmonary fibrosis, or the thic
